Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2010.01.012PMID 20171415
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cystic Fibrosis

  2009cited by this paper
• Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.

  2009cited by this paper
• CREON®: efficacy and safety in children less than 7 years old with exocrine pancreatic insufficiency due to cystic fibrosis

  2009cited by this paper
• ICH Harmonised Tripartite Guideline

  2009cited by this paper
• Efficacy and Tolerability of Creon for Children in Infants and Toddlers With Pancreatic Exocrine Insufficiency Caused by Cystic Fibrosis: An Open-Label, Single-Arm, Multicenter Study

  2009cited by this paper
• Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis

  2008cited by this paper
• Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review.

  2008cited by this paper
• Current treatment options for chronic pancreatitis

  2007cited by this paper
• Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis.

  2007cited by this paper
• An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.

  2006cited by this paper
• Diagnosis and Treatment of Intestinal Malabsorption in Cystic Fibrosis

  2006cited by this paper
• Safety and Preliminary Clinical Activity of a Novel Pancreatic Enzyme Preparation in Pancreatic Insufficient Cystic Fibrosis Patients

  2006cited by this paper
• Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis.

  2006cited by this paper
• The Effects of Oral Pancreatic Enzymes (Creon 10 Capsule) on Steatorrhea: A Multicenter, Placebo-controlled, Parallel Group Trial in Subjects With Chronic Pancreatitis

  2006cited by this paper
• Chronic pancreatitis.

  2006cited by this paper
• Gastrointestinal outcomes and confounders in cystic fibrosis.

  2005cited by this paper
• Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy

  2004cited by this paper
• Cystic fibrosis

  2003cited by this paper
• Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis.

  2003cited by this paper
• Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis

  2002cited by this paper
• Nutrition in patients with cystic fibrosis: a European Consensus.

  2002cited by this paper
• Stature as a prognostic factor in cystic fibrosis survival.

  2001cited by this paper
• Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis.

  2000cited by this paper
• A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency

  2000cited by this paper
• Statistical Principles for Clinical Trials

  1998cited by this paper
• Pancreatic enzymes in chronic pancreatitis

  1994cited by this paper
• The changing epidemiology of cystic fibrosis.

  1993cited by this paper
• Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis.

  1992cited by this paper
• Decline of Exocrine Pancreatic Function in Cystic Fibrosis Patients with Pancreatic Sufficiency

  1992cited by this paper
• Rapid method for the determination of fat in feces.

  1949cited by this paper
• Neue Methode zur Bestimmung des Stickstoffs in organischen Körpern

  1883cited by this paper

• Pancreatic Enzyme Replacement Therapy: Not Only in Chronic Pancreatitis.

  2025cites this paper
• Pediatric Pulmonology

  2025cites this paper
• Symptoms, burden, and unmet needs of patients living with exocrine pancreatic insufficiency: a narrative review of the patient experience

  2024cites this paper
• Clinical Efficacy and Safety of Treatments for Exocrine Pancreatic Insufficiency: A Systematic Literature Review

  2024influential citation
• Scoring Abdominal Symptoms in People with Cystic Fibrosis

  2024cites this paper
• Safety evaluation of the food enzyme phospholipase A2 from porcine pancreas

  2023cites this paper
• Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine

  2023cites this paper
• Safety evaluation of the food enzyme trypsin from porcine pancreas

  2022cites this paper
• S3-Leitlinie Pankreatitis – Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – September 2021 – AWMF Registernummer 021-003

  2022cites this paper
• Safety evaluation of the food enzyme containing trypsin, chymotrypsin, α‐amylase and triacylglycerol lipase from porcine pancreas

  2022cites this paper
• Safety evaluation of a food enzyme containing trypsin and chymotrypsin from porcine pancreas

  2021cites this paper
• Cystic Fibrosis

  2021cites this paper
• Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis.

  2021cites this paper
• Pharmacological Management of Acute and Chronic Pancreatitis

  2021cites this paper
• Safety evaluation of a food enzyme containing trypsin and chymotrypsin from porcine pancreas

  2021cites this paper
• Safety evaluation of a food enzyme containing trypsin, chymotrypsin, elastase and carboxypeptidase from porcine pancreas

  2021cites this paper
• Efikasi dan Keamanan dari Pancreatic Enzyme Replacement Therapy pada Pasien Cystic Fibrosis : Sebuah Kajian Sistematis

  2021influential citation
• Pancreatic enzyme replacement therapy for people with cystic fibrosis.

  2020cites this paper
• Dosing regimens for pancreatic enzyme replacement therapy (PERT) in cystic fibrosis

  2019cites this paper
• Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency

  2019cites this paper
• Nutrition in cystic fibrosis: From the past to the present and into the future

  2019cites this paper
• CONSORT 2010 statement: extension to randomised crossover trials

  2019cites this paper
• Pancreatic-like enzymes of microbial origin restore growth and normalize lipid absorption in a pig model with exocrine pancreatic insufficiency

  2018cites this paper
• The economic consequences of the introduction of Creon Micro into the basal therapy of exocrine pancreas deficiency due to cystic fibrosis in the children presenting with mucoviscidosis

  2017cites this paper
• Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis

  2017cites this paper
• 13 Emerging Approaches for the Treatment of Fat Malabsorption Due to Exocrine Pancreatic Insufficiency

  2017cites this paper
• The Pancreatic Duct Ligated (Mini)pig as a Model for Pancreatic Exocrine Insufficiency in Man

  2016cites this paper
• ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis.

  2016cites this paper
• Pancreatic enzyme replacement therapy for people with cystic fibrosis.

  2016cites this paper
• Is Pancrelipase Delayed Release Capsule (Creon) Safe for Use in Patients’ ≥7 Years Old Who Suffer From Pancreatic Insufficiency Due to Cystic Fibrosis?

  2016cites this paper
• [Pediatric pancreatitis. Evidence based management guidelines of the Hungarian Pancreatic Study Group].

  2015cites this paper
• Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: Prevalence and diagnostic use.

  2015cites this paper
• English language version of the S3-consensus guidelines on chronic pancreatitis: Definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis

  2015cites this paper
• Gyermekkori pancreatitis

  2015cites this paper
• Safety and efficacy of Creon® micro in children with exocrine pancreatic insufficiency due to cystic fibrosis.

  2015cites this paper
• A pancreas gyulladásos betegségei: patomechanizmustól a terápiáig

  2014cites this paper
• Pancreatic enzyme replacement therapy for people with cystic fibrosis.

  2014cites this paper
• A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40000 enteric-coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis.

  2013cites this paper
• Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.

  2013cites this paper
• Retrospective Analysis to Investigate the Effect of Concomitant Use of Gastric Acid–Suppressing Drugs on the Efficacy and Safety of Pancrelipase/Pancreatin (CREON®) in Patients With Pancreatic Exocrine Insufficiency

  2013cites this paper
• Statistical Challenges in the Evaluation of Treatments for Small Patient Populations

  2013influential citation
• Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension

  2013cites this paper
• Progress in cystic fibrosis and the CF Therapeutics Development Network

  2012cites this paper
• S3-Leitlinie Chronische Pankreatitis: Definition, Ätiologie, Diagnostik, konservative, interventionell endoskopische und operative Therapie der chronischen Pankreatitis. Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)

  2012cites this paper
• Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency

  2012cites this paper
• S3-Leitlinie Chronische Pankreatitis: Definition, Ätiologie, Diagnostik, konservative, interventionell endoskopische und operative Therapie der chronischen Pankreatitis. Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)

  2012cites this paper
• Maintenance of nutritional status in patients with cystic fibrosis: new and emerging therapies

  2012cites this paper
• Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis - a double-blind, placebo-controlled study

  2012cites this paper
• Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency

  2012cites this paper
• Pancreatic Enzyme Products: Digesting the Changes

  2011cites this paper
• Evaluation of Stool Collections to Measure Efficacy of PERT in Subjects With Exocrine Pancreatic Insufficiency

  2011cites this paper
• Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.

  2011cites this paper
• Pancreatic enzyme supplementation

  2011cites this paper
• Administration of CREON® Pancrelipase Pellets via Gastrostomy Tube is Feasible with No Loss of Gastric Resistance or Lipase Activity

  2011cites this paper
• Erratum: Pancrelipase Delayed-Release Capsules (CREON) for Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatic Surgery: A Double-Blind Randomized Trial

  2011cites this paper
• Enzyme replacement therapy for pancreatic kpuwhÞekgpe{<"rtgugpv"cpf"hwvwtg

  2011cites this paper
• A 6‐month, open‐label clinical trial of pancrelipase delayed‐release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery

  2011cites this paper
• Pancrelipase Delayed-Release Capsules (CREON) for Exocrine Pancreatic Insufficiency due to Chronic Pancreatitis or Pancreatic Surgery: A Double-Blind Randomized Trial

  2010cites this paper
• CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency

  2010cites this paper
• Pancrelipase for pancreatic disorders: An update.

  2010cites this paper
• Safety and Tolerability of a New Formulation of Pancrelipase Delayed-Release Capsules (CREON®) in Children Under Seven Years of Age with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis

  2010cites this paper
• Clinical and Experimental Gastroenterology Dovepress Enzyme Replacement Therapy for Pancreatic Insufficiency: Present and Future

  year unknowncites this paper
• e-SPEN guideline ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fi brosis

  year unknowncites this paper
• S3-Leitlinie Chronische Pankreatitis: Definition, Ätiologie, Diagnostik, konservative, interventionell endoskopische und operative Therapie der chronischen Pankreatitis. Leitlinie der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten (DGVS) 1

  year unknowncites this paper